181 related articles for article (PubMed ID: 16415503)
1. Atherosclerosis and angiogenesis: what do nerves have to do with it?
Zukowska Z
Pharmacol Rep; 2005; 57 Suppl():229-34. PubMed ID: 16415503
[TBL] [Abstract][Full Text] [Related]
2. Stress, NPY and vascular remodeling: Implications for stress-related diseases.
Kuo LE; Abe K; Zukowska Z
Peptides; 2007 Feb; 28(2):435-40. PubMed ID: 17241699
[TBL] [Abstract][Full Text] [Related]
3. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles.
Lee EW; Michalkiewicz M; Kitlinska J; Kalezic I; Switalska H; Yoo P; Sangkharat A; Ji H; Li L; Michalkiewicz T; Ljubisavljevic M; Johansson H; Grant DS; Zukowska Z
J Clin Invest; 2003 Jun; 111(12):1853-62. PubMed ID: 12813021
[TBL] [Abstract][Full Text] [Related]
4. NPY and NPY receptors in vascular remodeling.
Abe K; Tilan JU; Zukowska Z
Curr Top Med Chem; 2007; 7(17):1704-9. PubMed ID: 17979779
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors.
Movafagh S; Hobson JP; Spiegel S; Kleinman HK; Zukowska Z
FASEB J; 2006 Sep; 20(11):1924-6. PubMed ID: 16891622
[TBL] [Abstract][Full Text] [Related]
6. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium.
Zukowska-Grojec Z; Karwatowska-Prokopczuk E; Rose W; Rone J; Movafagh S; Ji H; Yeh Y; Chen WT; Kleinman HK; Grouzmann E; Grant DS
Circ Res; 1998 Jul; 83(2):187-95. PubMed ID: 9686758
[TBL] [Abstract][Full Text] [Related]
7. Of mice and men: neuropeptide Y and its receptors are associated with atherosclerotic lesion burden and vulnerability.
Li L; Najafi AH; Kitlinska JB; Neville R; Laredo J; Epstein SE; Burnett MS; Zukowska Z
J Cardiovasc Transl Res; 2011 Jun; 4(3):351-62. PubMed ID: 21468772
[TBL] [Abstract][Full Text] [Related]
8. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus.
Silva AP; Carvalho AP; Carvalho CM; Malva JO
Neuropharmacology; 2003 Feb; 44(2):282-92. PubMed ID: 12623227
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery.
Li L; Lee EW; Ji H; Zukowska Z
Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1204-10. PubMed ID: 12689918
[TBL] [Abstract][Full Text] [Related]
10. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system.
Pons J; Kitlinska J; Ji H; Lee EW; Zukowska Z
Can J Physiol Pharmacol; 2003 Feb; 81(2):177-85. PubMed ID: 12710532
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide Y Stimulates Proliferation and Migration of Vascular Smooth Muscle Cells from Pregnancy Hypertensive Rats via Y1 and Y5 Receptors.
Zhang P; Qi YX; Yao QP; Chen XH; Wang GL; Shen BR; Han Y; Gao LZ; Jiang ZL
PLoS One; 2015; 10(7):e0131124. PubMed ID: 26131716
[TBL] [Abstract][Full Text] [Related]
12. Neuropeptide Y: multiple receptors and multiple roles in cardiovascular diseases.
Pons J; Lee EW; Li L; Kitlinska J
Curr Opin Investig Drugs; 2004 Sep; 5(9):957-62. PubMed ID: 15503651
[TBL] [Abstract][Full Text] [Related]
13. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system?
Zukowska Z; Pons J; Lee EW; Li L
Can J Physiol Pharmacol; 2003 Feb; 81(2):89-94. PubMed ID: 12710520
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226.
Lundberg JM; Modin A
Br J Pharmacol; 1995 Dec; 116(7):2971-82. PubMed ID: 8680732
[TBL] [Abstract][Full Text] [Related]
15. Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control.
Malmström RE
Acta Physiol Scand Suppl; 1997; 636():1-55. PubMed ID: 9179320
[TBL] [Abstract][Full Text] [Related]
16. Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding.
Ghersi G; Chen W; Lee EW; Zukowska Z
Peptides; 2001 Mar; 22(3):453-8. PubMed ID: 11287101
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Y1, Y2 and Y5 subtypes of the neuropeptide Y (NPY) receptor in rabbit kidney. Sensitivity of ligand binding to guanine nucleotides and phospholipase C inhibitors.
Parker SL; Parker MS; Crowley WR
Regul Pept; 1998 Sep; 75-76():127-43. PubMed ID: 9802402
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y receptors.
Morris MJ; Gannan E; Stroud LM; Beck-Sickinger AG; O'Brien TJ
Eur J Neurosci; 2007 Feb; 25(4):1136-43. PubMed ID: 17331209
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide Y Y1 and Y2 receptor-mediated stimulation of mitogen-activated protein kinase activity.
Nie M; Selbie LA
Regul Pept; 1998 Sep; 75-76():207-13. PubMed ID: 9802411
[TBL] [Abstract][Full Text] [Related]
20. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
